Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Zentalis Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: Zentalis issued a press release on January 28, 2025, "announc[ing] a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026." Zentalis stated that "[t]he workforce reduction is expected to be substantially completed in the second quarter of 2025." Following this news, Zentalis's stock price fell sharply during intraday trading on January 29, 2025.
In order to be eligible to join the ZNTL class action lawsuit, you must have incurred a loss on shares of Zentalis Pharmaceuticals, Inc. purchased during the class period listed above.
TOP
